Advanced Solid Tumor Cancer
Conditions
Keywords
Advanced solid tumors, Bispecific antibody, Immune checkpoint inhibitor
Brief summary
This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.
Detailed description
Parts A and B will investigate the safety and tolerability of BNT3214. Part B is optional and will only be opened if emerging data from Part A indicates that an alternative BNT3214 dosing schedule may have a better benefit-risk profile for further development. Based on the available safety, pharmacokinetics (PK) or preliminary overall response data from Parts A and B, the study may progress to Part C. A study internal review committee will oversee the study to evaluate safety data as the study progresses and/or may recommend the dose levels (DLs) for the dose expansion, possible changes in the schedule of dosing, and expansion indications based on the totality of available data. There will be no randomization in Parts A and B or the dose expansion cohorts of Part C. In the dose optimization cohorts of Part C, eligible participants will be randomized to one of two DLs selected from Parts A and B. In the dose expansion cohorts, participants will be enrolled into indication-specific cohorts as predefined or may be adjusted per safety, efficacy signals from Parts A and/or B. Participants will receive BNT3214 for a maximum of 2 years or until disease progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), unacceptable toxicity, withdrawal of consent, loss of clinical benefit as determined by the investigator, lost to follow-up, death, or until the sponsor terminates the study or any other criterion for discontinuation is met, whichever occurs first.
Interventions
DRUGBNT3214
Intravenous infusion
Sponsors
BioNTech SE
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Biotheus (Hengqin) Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants aged ≥18 years of age inclusive at the time of giving informed consent. * Have at least one measurable tumor lesion based on RECIST v1.1. One lesion with prior local treatment (i.e., radiotherapy) can be considered measurable only if a disease progression from prior local treatment was demonstrated in the lesion per RECIST v1.1. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Have a predicted life expectancy ≥3 months. * Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors that have progressed after at least one available standard therapy; or for whom the standard therapy is considered to be ineffective, inappropriate or intolerable; or for whom a clinical study of an investigational agent is a recognized standard of care. * Have adequate liver function as defined in the protocol. * Have adequate renal function as defined in the protocol. * Have adequate hematologic function as defined in the protocol. * Have adequate coagulation as defined in the protocol.
Exclusion criteria
* Untreated or symptomatic central nervous system (CNS) metastases and leptomeningeal disease. * Have a primary CNS malignancy. * Have active, or a history of, pneumonitis requiring treatment with steroids, or have active, or a history of, interstitial lung disease. * Have clinically significant pulmonary complications including, but not limited to, chronic obstructive pulmonary disease, restrictive lung disease, lung injury accompanied with autoimmune disease/connective tissue disorders. * Have a history of severe cardiovascular disease. * Have a history of significant hematologic toxicity to prior lines of therapy, as assessed by the investigator. * Have uncontrolled hypertension or poorly controlled diabetes prior to allocation or randomization. * Have concurrent malignancy within 5 years prior to allocation or randomization (protocol defined exceptions apply). * Have unstable thrombotic event (e.g., deep vein thrombosis, arterial thrombosis, pulmonary embolism) requiring therapeutic intervention within 3 months prior to allocation or randomization, unless the participant has been fully treated (e.g., inferior vena cava filter placed) and/or adequately anticoagulated on a prophylactic dose. * Have known human immunodeficiency virus infection or known acquired immunodeficiency syndrome (protocol defined exceptions apply). * Have an active hepatitis B virus infection. * Have an active hepatitis C virus (HCV) infection. Participants with a negative HCV antibody test at screening or positive HCV antibody test followed by a negative HCV ribonucleic acid test at screening are eligible. Participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification are allowed. * Have adverse reactions from prior anti-tumor therapy that have not returned to Grade ≤1, except for alopecia or toxicities (not specified elsewhere) considered irreversible and posing no safety risk to participants. * Have active, or history of, autoimmune disease (e.g., myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, vasculitis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis) (protocol defined exceptions apply). * Have serious non-healing wounds, ulcer, or bone fracture. * Participants with lung cancer who have major coagulation disorders or an increased risk of hemorrhage (per investigator's clinical judgment) * Have a history of serious Grade ≥3 immune-related adverse events (irAEs) that led to treatment discontinuation of a prior immunotherapy. Participants with a history of Grade ≥3 irAEs that did not lead to treatment discontinuation of a prior immunotherapy should be evaluated and determined by investigators for potential safety risk. * Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to allocation or randomization. * Current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment (protocol defined exceptions apply). * Have received any of the following therapies or drugs within the noted time intervals prior to allocation or randomization: * Systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 10 days prior to the initiation of study treatment. * Have been vaccinated with live, attenuated vaccine(s) within 4 weeks prior to initiation of the study treatment. NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| All parts - Number and percentage of participants with treatment emergent adverse events (TEAEs) | From the time of initiation of the first dose of BNT3214 until 90 days after the last dose of BNT3214 | Per DL/cohort. By United States National Cancer Institute Common Terminology Criteria for Adverse Events grading, seriousness, and relatedness. |
| All parts - Number and percentage of participants with dose interruptions, reductions, and discontinuation of BNT3214 due to TEAEs | Up to 24 months | Per DL/cohort. |
| Parts A and B only - Number and percentage of participants with dose limiting toxicities (DLTs) | From first dose up to 28 days | During the DLT evaluation period |
| Part C only - Objective response rate (ORR) | Up to 30 months | Per DL/cohort. Defined as the percentage of participants in whom a confirmed complete response (CR) or partial response (PR) per RECIST v1.1 (based on the investigator's assessment) is observed as best overall response. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All parts - PK assessment: Area under the curve (AUC) | Up to 3 months from first dose of BNT3214 | Per DL/cohort. Derived for BNT3214 levels in plasma or serum (for Cycle 1, single-dose and Cycle 3, multiple-dose). If data permits. |
| All parts - PK assessment: Maximum concentration (Cmax) | Up to 3 months from first dose of BNT3214 | Per DL/cohort. Derived for BNT3214 levels in plasma or serum (for Cycle 1, single-dose and Cycle 3, multiple-dose). If data permits. |
| All parts - PK assessment: Time to maximum observed concentration (Tmax) | Up to 3 months from first dose of BNT3214 | Per DL/cohort. Derived for BNT3214 levels in plasma or serum (for Cycle 1, single-dose and Cycle 3, multiple-dose). If data permits. |
| All parts - PK assessment: Half-life (t1/2) | Up to 3 months from first dose of BNT3214 | Per DL/cohort. Derived for BNT3214 levels in plasma or serum (for Cycle 1, single-dose and Cycle 3, multiple-dose). If data permits. |
| Parts A and B only - ORR | Up to 30 months | Per DL/cohort. Defined as the percentage of participants in whom a confirmed CR or PR per RECIST v1.1 (based on the investigator's assessment) is observed as best overall response. |
| All parts - Disease control rate | Up to 30 months | Per DL/cohort. Defined as the percentage of participants in whom a confirmed CR or PR or stable disease (assessed at least 6 weeks after the first BNT3214 dose) per RECIST v1.1 (based on the investigator's assessment) is observed as best overall response. |
| All parts - Duration of response | Up to 30 months | Per DL/cohort. Defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (progressive disease) (based on the investigator's assessment) or death from any cause, whichever occurs first. |
| All parts - Anti-drug antibody (ADA) prevalence (percentage of participants who are ADA-positive) | Up to 90 days from the last dose of BNT3214 | Either baseline or post-baseline. If data permits. |
| All parts - ADA incidence (percentage of participants having treatment-emergent ADA) | Up to 90 days from the last dose of BNT3214 | If data permits. |
Countries
Australia, China, South Korea, Taiwan
Contacts
CONTACTBioNTech clinical trials patient information
STUDY_DIRECTORBioNTech Responsible Person
BioNTech SE
Outcome results
None listed